CA
XFOR icon

Clearstead Advisors’s X4 Pharmaceuticals XFOR Stock Holding History

Clearstead Advisors’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-64
Closed -$122 – 3267
2025
Q2 		$122 Buy
+64
New +$262 ﹤0.01% 2599
2025
Q1 		– Sell
-3
Closed -$74 – 2321
2024
Q4 		$74 Hold
3
– – ﹤0.01% 2054
2024
Q3 		$67 Sell
3
-67
-96% -$1.4K ﹤0.01% 2005
2024
Q2 		$1.22K Hold
70
– – ﹤0.01% 1878
2024
Q1 		$2.05K Hold
70
– – ﹤0.01% 1306
2023
Q4 		$1.76K Sell
70
-70
-50% -$1.7K ﹤0.01% 1303
2023
Q3 		$4.58K Buy
140
+70
+100% +$3.05K ﹤0.01% 1262
2023
Q2 		$4.07K Hold
70
– – ﹤0.01% 1070
2023
Q1 		$1.83K Hold
70
– – ﹤0.01% 1150
2022
Q4 		$2.08K Hold
70
– – ﹤0.01% 1085
2022
Q3 		$4K Hold
70
– – ﹤0.01% 1012
2022
Q2 		$2K Hold
70
– – ﹤0.01% 1141
2022
Q1 		$4K Hold
70
– – ﹤0.01% 1126
2021
Q4 		$5K Buy
70
+67
+2,233% +$8.47K ﹤0.01% 1009
2021
Q3 		$1K Hold
3
– – ﹤0.01% 1256
2021
Q2 		$1K Hold
3
– – ﹤0.01% 1215
2021
Q1 		$1K Buy
+3
New +$788 ﹤0.01% 1085

Other funds holding XFOR

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
SC
Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Clearstead Advisors's XFOR Position: Q3 2025 in Review

Clearstead Advisors sold out of X4 Pharmaceuticals (XFOR) in Q3 2025, closing a stake of 64 shares — an estimated $122 sold.

Clearstead Advisors first reported a position in XFOR in Q1 2021 and held it in 17 quarters. The position peaked at $5K in Q4 2021. 42 funds tracked by Wall St. Rank hold XFOR as of Q3 2025.

  • Clearstead Advisors reported no remaining X4 Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Clearstead Advisors sold 64 X4 Pharmaceuticals shares in Q3 2025, an estimated $122.
  • Clearstead Advisors first reported a position in X4 Pharmaceuticals in Q1 2021 and held it in 17 quarters.
  • Clearstead Advisors's X4 Pharmaceuticals position peaked at $5K in Q4 2021.
  • 42 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q3 2025.

Based on Clearstead Advisors's 13F filing for Q3 2025, filed 10 Nov 2025.